
LQDA Stock Forecast & Price Target
LQDA Analyst Ratings
Bulls say
Liquidia Corp, a biopharmaceutical company focusing on treatments for pulmonary hypertension, is poised for potential cash-flow positivity and profitability sooner than expected, bolstered by disciplined spending, improving gross margins, and an efficient specialty-pharmacy model. The company anticipates strong third-quarter performance for its product YUTREPIA, with management reporting sustained referral momentum, increased prescriber adoption, and established broad payer access across major national plans. Early metrics reveal robust adoption, evidenced by approximately 900 referrals and a 75% conversion rate to paid therapy within just 11 weeks, highlighting strong operational performance and market traction.
Bears say
Liquidia Corp faces significant investor anxiety regarding potential competition from sotatercept, which could lead to a diminished market for prostacyclin products, including its flagship offering, YUTREPIA. Additionally, the company is confronted with multiple risks that could negatively impact its revenue projections, including the possibility of failing to meet peak commercial revenue estimates due to factors such as market size, penetration rates, and pricing strategies. Furthermore, concerns about securing sufficient capital resources to support ongoing operations and development, along with competitive pressures in the biopharmaceutical sector, contribute to a negative outlook for Liquidia's stock.
This aggregate rating is based on analysts' research of Liquidia Technologies Inc and is not a guaranteed prediction by Public.com or investment advice.
LQDA Analyst Forecast & Price Prediction
Start investing in LQDA
Order type
Buy in
Order amount
Est. shares
0 shares